Benzinga.com

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Reuters

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount

July 1 (Reuters) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s (ABBV.N), opens new tab blockbuster arthritis drug ...
manilatimes

Organon marks 5 years of advancing health through medicines, solutions, partnerships

FIVE years after launching as a global healthcare company committed to delivering impactful medicines and solutions for a healthier every day, Organon is marking a milestone defined not simply by ...
Business Wire

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) ...
NJBIZ

Organon, Eli Lilly expand partnership for migraine medication

Jersey City-based Organon is expanding its distribution and promotion agreement with Eli Lilly and Co. for migraine medicine Emgality. Emgality, a monoclonal antibody that selectively binds to ...